Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 5

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 5
---
agingsponsor investors, or none at all, and the purchase of the non -managingsponsor membership interests is not contingent upon the participation in this offering or vice -versa. Depending on how many units are purchased by the non -managingsponsor investors, the post -offeringtrading volume, volatility and liquidity of our securities may be reduced relative to what they would have been had the units been more widely offered and sold to other public investors. We do not expect any purchase of units by the non -managingsponsor investors to negatively impact our ability to meet Nasdaq listing eligibility requirements. The underwriters will receive the same upfront discounts and commissions and deferred underwriting commissions on units purchased by the non -managingsponsor investors, if any, as it will on the other units sold to the public in this offering. In addition, none of the non -managingsponsor investors has any obligation to vote any of their public shares in favor of our initial business combination. Nevertheless, the non -managingsponsor investors will be incentivized to vote any of their public shares in favor of a business combination due to their indirect ownership through the sponsor of 666,667 founder shares and 50,000 private units. For a discussion of certain additional arrangements with the non -managingsponsor investors, see “ Summary — The Offering — Expressions of Interest.” Our sponsor currently holds 9,857,143 ordinary shares (which were purchased for $35,000 and which we refer to as “founder shares”), up to 1,285,714 of which are subject to surrender and forfeiture by our sponsor depending on the extent to which the underwriters’ over -allotmentoption is exercised. Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of this offering, assuming no value is ascribed to the rights included in the units. See“ Risk Factors— General Risks— Our sponsor paid a nominal price for the founder shares and, accordingly, you will experience immediate and substantial dilution upon the purchase of our ordinary shares.”

The following table illustrates the difference between the public offering price per unit and our net tangible book value per share (NTBV), as adjusted to give effect to this offering and assuming the redemption of our public shares at varying levels and the exercise in full and no exercise of the over -allotmentoption. See the sections titled“ Prospectus Summary — Dilution” and“ Dilution”